Short Communication - (2025) Volume 12, Issue 2
Received: 01-Apr-2025, Manuscript No. jpd-26-183910;
Editor assigned: 03-Apr-2025, Pre QC No. P-183910;
Reviewed: 17-Apr-2025, QC No. Q-183910;
Revised: 22-Apr-2025, Manuscript No. R-183910;
Published:
29-Apr-2025
, DOI: 10.37421/2684-4281.2025.12.518
Citation: Pham, Linh T.. ”Cutaneous Drug Reactions: Recognition, Management, and Diagnosis.” J Dermatol Dis 12 (2025):518.
Copyright: © 2025 Pham T. Linh This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Cutaneous drug reactions represent a prevalent and heterogeneous category of adverse events frequently encountered in clinical practice. Understanding their diverse manifestations, ranging from mild skin rashes to severe blistering disorders, is paramount for timely diagnosis and effective intervention. This review offers a comprehensive examination of common cutaneous drug reactions, emphasizing key diagnostic characteristics, diagnostic methodologies including patch testing and biopsy interpretation, and current management strategies. A particular focus is placed on identifying drug hypersensitivity syndromes, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and distinguishing them from less severe reactions. [1] Morbilliform drug eruptions stand out as the most common type of cutaneous drug reaction. They typically manifest as erythematous macules and papules, frequently exhibiting a symmetric distribution, and may be accompanied by mild itching. Management necessitates the prompt discontinuation of the causative drug and symptomatic treatment, often involving topical or oral corticosteroids. Accurate identification of the offending drug is crucial, and clinicians must be knowledgeable about frequently implicated agents. [2] Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are characterized as severe, life-threatening mucocutaneous reactions that lead to extensive epidermal detachment. Early detection, immediate cessation of the offending drug, and swift transfer to specialized centers for supportive care, encompassing fluid and electrolyte balance and wound management, are critical. The utility of systemic corticosteroids and intravenous immunoglobulin (IVIG) remains a subject of debate, though they are frequently employed. [3] Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, delayed hypersensitivity reaction that can impact multiple organ systems. Its typical presentation includes a rash, fever, swollen lymph nodes, and elevated eosinophil counts, often appearing two to eight weeks after initiating a drug. Management primarily involves discontinuing the implicated drug and providing supportive care. Corticosteroids may be administered to mitigate inflammation. [4] Fixed drug eruptions (FDEs) are defined by the predictable reappearance of lesions in the same site(s) upon re-exposure to the drug responsible. These typically present as sharply demarcated erythematous plaques, occasionally bullous, which resolve leaving behind hyperpigmentation. Diagnosis is primarily clinical, and management centers on identifying and avoiding the culprit drug. Topical corticosteroids can be beneficial in managing acute flare-ups. [5] Urticarial drug reactions are frequently observed and can manifest as temporary, itchy hives. While many cases are mild and resolve spontaneously, some may signal more serious underlying hypersensitivity. Management strategies include discontinuing the offending agent and administering antihistamines. Angioedema, which can be a component of these reactions, requires careful monitoring. [6] The utility of patch testing in the diagnosis of cutaneous drug reactions, particularly those involving delayed-type hypersensitivity, is a significant area of discussion. Although not always conclusive, it can be instrumental in pinpointing specific drug allergens when clinical suspicion is high and the reaction pattern is suggestive. Prudent interpretation of the results, taking into account potential cross-reactivity, is essential. [7] Skin biopsy continues to be a vital component in the diagnostic assessment of ambiguous cutaneous drug reactions, especially in severe presentations such as SJS/TEN or DRESS. While histopathological findings may often be non-specific, they can corroborate the clinical diagnosis and aid in excluding other dermatological conditions. A thorough correlation with the clinical presentation and drug history is indispensable for accurate interpretation. [8] The management of cutaneous drug reactions necessitates a comprehensive strategy. The most crucial step involves the rapid identification and cessation of the causative drug. Subsequent management is dictated by the reaction's severity and type, ranging from topical treatments for milder eruptions to intensive supportive care for severe manifestations. [9] Drug-induced pseudolymphoma, a rare yet significant differential diagnosis in cutaneous drug reactions, bears a resemblance to cutaneous lymphoma. It is commonly linked to anticonvulsants and ACE inhibitors. Histopathological examination is pivotal for diagnosis, and withdrawal of the implicated drug typically leads to complete remission. [10]
Cutaneous drug reactions represent a broad and varied spectrum of adverse events commonly encountered in clinical practice. A thorough understanding of their diverse presentations, from mild exanthems to severe bullous disorders, is essential for prompt diagnosis and effective management. This review aims to furnish a detailed overview of prevalent cutaneous drug reactions, highlighting key diagnostic features, diagnostic approaches such as patch testing and biopsy interpretation, and current management strategies. Particular emphasis is placed on the recognition of drug hypersensitivity syndromes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and differentiating them from less severe cutaneous reactions. [1] Morbilliform drug eruptions are recognized as the most frequent subtype of cutaneous drug reaction. Clinically, they typically present as erythematous macules and papules, often symmetrically distributed, and may be accompanied by mild pruritus. The primary management strategy involves the immediate withdrawal of the offending drug and symptomatic treatment, which may include topical or oral corticosteroids. Identifying the specific drug responsible is of paramount importance, and clinicians must maintain awareness of common offending agents. [2] Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, potentially fatal mucocutaneous reactions characterized by widespread epidermal detachment. Early recognition of these conditions, immediate discontinuation of the implicated drug, and prompt referral to specialized centers for comprehensive supportive care, including meticulous fluid and electrolyte management and advanced wound care, are critically important. While systemic corticosteroids and intravenous immunoglobulin (IVIG) remain subjects of ongoing discussion regarding their efficacy, they are frequently utilized in clinical practice. [3] Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe form of delayed-hypersensitivity reaction that has the potential to affect multiple organ systems. The typical clinical presentation includes a rash, fever, lymphadenopathy, and eosinophilia, often emerging within a timeframe of two to eight weeks following the initiation of a drug. Management strategies are primarily focused on withdrawing the implicated drug and providing supportive care. Systemic corticosteroids may be employed to modulate and control inflammatory processes. [4] Fixed drug eruptions (FDEs) are pathognomonic for the recurrence of skin lesions in the exact same anatomical location(s) upon subsequent exposure to the causative drug. They characteristically manifest as well-demarcated erythematous plaques, which can occasionally be bullous, and typically resolve with post-inflammatory hyperpigmentation. The diagnosis is largely clinical, and the cornerstone of management involves the accurate identification and subsequent avoidance of the offending drug. Topical corticosteroids can offer symptomatic relief during acute flares. [5] Urticarial drug reactions are a common manifestation and can present as transient, intensely pruritic wheals. While many instances are benign and self-resolving, some may serve as indicators of more serious underlying hypersensitivity mechanisms. The recommended management includes discontinuing the offending agent and administering antihistamines. Angioedema, which can be an associated feature, necessitates careful and vigilant monitoring due to potential airway compromise. [6] The role of patch testing in the diagnostic process for cutaneous drug reactions, particularly those mediated by delayed-type hypersensitivity, is an important consideration. Although patch testing may not always yield definitive results, it can be a valuable tool in identifying specific drug allergens when clinical suspicion is high and the reaction pattern aligns with known hypersensitivity syndromes. Careful interpretation of test results is imperative, taking into account the possibility of cross-reactivity between different drug molecules. [7] Skin biopsy remains an indispensable tool in the diagnostic workup for cutaneous drug reactions that present with ambiguous clinical features, particularly in severe cases such as SJS/TEN or DRESS syndrome. While histopathological findings may frequently be non-specific, they can provide crucial support for the clinical diagnosis and assist in the exclusion of other dermatological conditions. Accurate interpretation hinges on a thorough correlation between histopathological findings, the clinical presentation, and the patient's drug history. [8] The management of cutaneous drug reactions requires a structured and multifaceted approach. The most critical initial step involves the prompt and accurate identification of the causative drug, followed by its immediate withdrawal. Subsequent management decisions are contingent upon the severity and specific type of reaction observed, with therapeutic interventions ranging from topical treatments for milder eruptions to intensive, multidisciplinary supportive care for severe and life-threatening cases. [9] Drug-induced pseudolymphoma is a rare but clinically significant condition that must be considered in the differential diagnosis of cutaneous drug reactions, as it can closely mimic cutaneous lymphoma. This condition is typically associated with the use of anticonvulsant medications and ACE inhibitors. Histopathological examination plays a pivotal role in establishing the diagnosis, and withdrawal of the implicated drug generally leads to complete and spontaneous resolution of the lesions. [10]
Cutaneous drug reactions are common and varied, ranging from mild rashes to severe, life-threatening conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Morbilliform eruptions are the most frequent, characterized by erythematous macules and papules, managed by drug withdrawal and symptomatic treatment. SJS/TEN require immediate drug cessation and specialized supportive care. DRESS syndrome involves a systemic reaction with rash, fever, and eosinophilia. Fixed drug eruptions recur in the same location upon re-exposure. Urticarial reactions present as itchy wheals, managed with antihistamines. Patch testing and skin biopsies are valuable diagnostic tools, especially for delayed hypersensitivity reactions and severe cases. Identifying and withdrawing the offending drug is the cornerstone of management for all cutaneous drug reactions. Drug-induced pseudolymphoma is a rare mimic of cutaneous lymphoma, resolved by drug withdrawal.
None
None
Journal of Dermatology and Dermatologic Diseases received 4 citations as per Google Scholar report
